vida: extract claims from 2026-03-05-omada-health-fy2025-results-first-profitable-quarter

- Source: inbox/queue/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -53,3 +53,10 @@ Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 4
 **Source:** Noom 2025 performance data, Pharmaceutical Commerce
 
 Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management as the primary cause of 30%+ dropout in first 4 weeks during titration phase, and addressed this through microdosing strategy (lower dose → fewer side effects → higher adherence) rather than purely behavioral interventions.
+
+
+## Supporting Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% in comparison cohort, representing an 18-20 percentage point improvement. Members in the program achieved 18.4% average weight loss at 12 months for persistent members (16.3% overall), which is 44% better than real-world semaglutide evidence. This provides quantified evidence that structured behavioral support programs significantly improve medication adherence.

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -53,3 +53,10 @@ Reconciliation of apparent contradiction: KFF shows 49% large employer coverage
 **Source:** NPR April 22, 2026; Mercer 2026
 
 NPR provides second-source confirmation of the covered lives decline: 3.6M (2024) → 2.8M (2026), a 22% drop. Multiple employers in NPR focus groups reported firms 'will no longer cover GLP-1 agonists for weight loss.' The Mercer data shows 66% of employers say GLP-1 had 'significant' impact on prescription drug spending, and 77% of large employers prioritize managing GLP-1 costs. This confirms the access gap is widening despite clinical demand growth.
+
+
+## Extending Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada's GLP-1 Flex Care model (announced March 2026) represents a structural response to employer coverage decline by unbundling medication cost from program cost. Employers pay for behavioral support infrastructure while members use existing pharmacy benefits for drugs, allowing employers to offer GLP-1 programs without taking on medication cost exposure. This creates a new purchasing pathway that bypasses traditional covered lives constraints.

domains/health/glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-managed-access-infrastructure-creates-distinct-platform-opportunity-beyond-behavioral-coaching", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
 ---
 
 # GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
@@ -38,3 +38,10 @@ Indication expansion creates additional complexity requiring distinct medical-ne
 **Source:** PHTI December 2025 employer report
 
 PHTI identifies five specific infrastructure components: utilization management, outcomes-based contracting, indication-specific programs, adherence/discontinuation systems, and employer financing products. Three major payers (Evernorth 9M lives, Optum Rx, UHC) have operationalized distinct infrastructure plays. 79% of large employers expanded utilization management despite flat obesity-indication coverage.
+
+
+## Extending Evidence
+
+**Source:** Omada Health FY2025 earnings report, March 5, 2026
+
+Omada announced GLP-1 Flex Care (March 5, 2026), an employer cash-pay model where employers pay for the behavioral program while members use pharmacy benefits for medication. This separates drug cost exposure from program cost, directly addressing the covered lives decline problem. The company also announced nationwide prescribing capability launching in 2026, moving from behavioral companion to full clinical program. This demonstrates the evolution from coaching-only to integrated managed access infrastructure.

inbox/archive/health/2026-03-05-omada-health-fy2025-results-first-profitable-quarter.md

@@ -7,10 +7,13 @@ date: 2026-03-05
 domain: health
 secondary_domains: []
 format: earnings-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [Omada, digital-health, GLP-1, behavioral-health, atoms-to-bits, VBC, employer-market, IPO]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content